A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 2, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the TVTX SEC filings page.
Travere Therapeutics, Inc. (TVTX) reported $651.0M in revenue over the twelve months to Sep 30, 2026, up 49.4% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
FY2025 revenue expansion brought operating losses close to break-even, but working capital became more dependent on collecting receivables.
Revenue more than doubled to$491M while operating cash flow shifted from-$237M in FY2024 to positive$38M in FY2025, marking a cash-conversion turn rather than growth funded solely by external capital. Yet receivables rose195.5% to$80M as current liabilities fell20.3% , so the cash improvement coexists with more reported sales tied up in customer balances.
The profit improvement came largely below gross profit: R&D spending fell to
Short-term coverage was represented by a 2.7x current ratio, indicating current assets exceeded current obligations. However, liabilities represented
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Travere Therapeutics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Travere Therapeutics, Inc. held $322.8M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations generated $37.8M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Travere Therapeutics, Inc. scores 87/100 among other emerging companies.
Dilution ranks emerging companies on the yearly rate at which their shares outstanding grew across the last three fiscal years (the last two where the earliest reports none), a slower rise ranking higher because each round of funding spreads the same business across more owners. Travere Therapeutics, Inc. scores 57/100 on it among other emerging companies.
Travere Therapeutics, Inc. spent $206.0M on research and development in fiscal year 2025, which was 37.2% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Travere Therapeutics, Inc. scores 67/100 among other emerging companies.
Revenue Progress ranks emerging companies on the yearly rate at which their revenue compounded across the last three fiscal years (the last two where the earliest reports none), counted in the currency each company reports in. Travere Therapeutics, Inc. scores 84/100 on it among other emerging companies.
Burn Trend ranks emerging companies on how far their operating cash flow moved between the newest fiscal year and the one two years earlier, measured against the cash the earlier year used, and a move toward generating cash ranks higher. Travere Therapeutics, Inc. scores 92/100 on it among other emerging companies.
Travere Therapeutics, Inc.'s cash, cash equivalents and investments came to $322.8M at the end of fiscal year 2025, against $490.4M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Travere Therapeutics, Inc. scores 50/100 among other emerging companies.
Travere Therapeutics, Inc. scores 3.56, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $4.9B against total liabilities of $490.4M. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Travere Therapeutics, Inc. passes 7 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
Travere Therapeutics, Inc. reported a net loss of $25.5M while generating $37.8M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Travere Therapeutics, Inc. reported an operating loss of $62.8M against $10.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Travere Therapeutics, Inc. generated $224.6M in revenue in Q3 2026. This represents an increase of 36.2% from the same quarter a year earlier. Against the prior quarter it is up 32.4%.
Travere Therapeutics, Inc.'s EBITDA was -$62.9M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 254.5% from the same quarter a year earlier. Against the prior quarter it is down 868.3%.
Travere Therapeutics, Inc. reported a net loss of $52.3M in Q3 2026. This represents a decrease of 303.6% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Travere Therapeutics, Inc. earned -$0.55 per diluted share (EPS) in Q3 2026. This represents a decrease of 296.4% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
Travere Therapeutics, Inc. held $123.5M in cash as of Q3 2026; no long-term debt figure is on record for that period.
Not reported for Q3 2026.
Not reported for Q3 2026.
Margins & Returns
Travere Therapeutics, Inc.'s gross margin was 98.7% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is down 0.3 percentage points from the same quarter a year earlier. It is unchanged from the prior quarter.
Travere Therapeutics, Inc.'s operating margin was -30.3% in Q3 2026, reflecting core business profitability. This is down 45.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 32.7 percentage points.
Travere Therapeutics, Inc.'s net profit margin was -23.3% in Q3 2026, showing the share of revenue converted to profit. This is down 38.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.8 percentage points.
Travere Therapeutics, Inc.'s quarterly ROE was -231.7% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 266.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 89.8 percentage points.
Capital Allocation
Travere Therapeutics, Inc. invested $70.3M in research and development in Q3 2026. This represents an increase of 35.5% from the same quarter a year earlier. Against the prior quarter it is up 16.6%.
Not reported for Q3 2026.
Not reported for Q3 2026.
TVTX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $224.6M+36.2% | $169.6M+48.2% | $127.2M+55.6% | $129.7M+73.4% | $164.9M+162.1% | $114.4M+111.5% | $81.7M+97.5% | $74.8M+66.0% |
| Cost of Revenue | $2.9M+80.9% | $2.2M+42.9% | $1.9M-58.3% | $2.6M0.0% | $1.6M-2.5% | $1.5M-26.2% | $4.7M+211.1% | $2.6M |
| Gross Profit | $221.7M+35.8% | $167.4M+48.2% | $125.2M+62.5% | $127.1M+76.0% | $163.3M+166.5% | $112.9M+116.9% | $77.1M+93.3% | $72.2M |
| R&D Expenses | $70.3M+35.5% | $60.3M+22.1% | $57.1M+21.8% | $57.9M-6.8% | $51.9M+0.4% | $49.4M-9.1% | $46.9M-5.1% | $62.1M |
| SG&A Expenses | $98.4M+38.5% | $96.1M+53.6% | $80.3M+32.8% | $127.8M+83.8% | $71.0M+8.3% | $62.6M-3.4% | $60.4M-5.9% | $69.5M |
| Operating Income | -$68.1M-373.2% | $4.0Mn/m | -$36.9Mn/m | -$32.4Mn/m | $24.9Mn/m | -$12.7Mn/m | -$42.7Mn/m | -$60.7Mn/m |
| EBITDA | -$62.9M-254.5% | $8.2M+499.4% | -$11.7Mn/m | -$14.3Mn/m | $40.7Mn/m | $1.4Mn/m | -$29.9Mn/m | -$48.6Mn/m |
| Interest Expense | $2.1M-22.2% | $2.1M-25.0% | $2.3M-19.5% | $2.3M-18.6% | $2.8M-0.9% | $2.8M+2.1% | $2.9M+2.0% | $2.8M |
| Income Tax | -$5.9M-73787.5% | -$204K-1120.0% | -$120K-407.7% | $921Kn/m | $8Kn/m | $20K-76.5% | $39K-79.6% | -$72K |
| Net Income | -$52.3M-303.6% | -$34.8Mn/m | -$37.1Mn/m | $2.7Mn/m | $25.7Mn/m | -$12.8Mn/m | -$41.2Mn/m | -$60.3Mn/m |
| EPS (Basic) | -$0.55-289.7% | -$0.37n/m | -$0.40n/m | $0.03n/m | $0.29n/m | -$0.14n/m | -$0.47n/m | -$0.71n/m |
| EPS (Diluted) | -$0.55-296.4% | -$0.37n/m | -$0.40n/m | $0.03n/m | $0.28n/m | -$0.14n/m | -$0.47n/m | -$0.71n/m |
| Diluted Shares (Avg) | 95M-7.8% | 93M+5.1% | 92M+4.0% | N/A | 103M+31.9% | 89M+14.8% | 88M+14.5% | N/A |
TVTX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $848.2M+57.5% | $799.4M+43.9% | $555.2M+1.2% | $605.2M+1.9% | $538.6M+6.8% | $555.3M+0.8% | $548.8M-17.3% | $594.1M-24.7% |
| Current Assets | $633.4M+70.7% | $615.1M+62.1% | $392.7M+4.9% | $437.6M+5.0% | $371.1M+14.3% | $379.6M+2.9% | $374.2M-22.2% | $416.7M-32.4% |
| Cash & Equivalents | $123.5M+11.4% | $117.7M+56.7% | $78.4M+26.6% | $93.0M+58.9% | $110.9M+204.7% | $75.2M+132.7% | $61.9M+43.1% | $58.5M+0.6% |
| Short-Term Investments | $179.8M+29.7% | $175.9Mn/m | $130.6Mn/m | $145.4Mn/m | $138.7M-36.7% | $0-100.0% | $0-100.0% | $0-100.0% |
| Inventory | $43.8M+16.7% | $40.0M+6.3% | $37.1M-2.5% | $36.2M-13.6% | $37.5M-12.4% | $37.7M-12.3% | $38.0M-10.2% | $41.9M+344.8% |
| Accounts Receivable | $107.5M+29.6% | $80.6M+108.3% | $87.3M+153.9% | $80.1M+195.5% | $83.0M+229.7% | $38.7M+58.3% | $34.4M+51.3% | $27.1M+28.0% |
| Long-Term Investments | $168.4M+3306.3% | $195.5Mn/m | $55.7Mn/m | $84.4Mn/m | $4.9M-77.6% | $0-100.0% | $0-100.0% | $0-100.0% |
| Goodwill | N/A | N/A | N/A | N/A | $800K0.0% | $800K0.0% | $800K0.0% | $800K0.0% |
| Total Liabilities | $825.6M+77.6% | $774.8M+48.3% | $456.5M-11.5% | $490.4M-8.4% | $465.0M-13.1% | $522.6M-2.5% | $516.0M-12.5% | $535.0M-9.0% |
| Current Liabilities | $210.9M+56.1% | $152.0M-19.8% | $125.4M-31.3% | $159.9M-20.3% | $135.1M-28.9% | $189.5M+56.3% | $182.5M+5.3% | $200.8M+12.8% |
| Non-Current Liabilities | $614.7M+86.3% | $622.8M+87.0% | $331.0M-0.7% | $330.5M-1.1% | $329.9M-4.3% | $333.0M-19.7% | $333.5M-19.9% | $334.3M-18.5% |
| Long-Term Debt | N/A | N/A | N/A | $311.7M+0.5% | $311.4M+0.5% | $311.0M-17.7% | $310.7M-17.7% | $310.3M-17.7% |
| Total Equity | $22.6M-69.3% | $24.5M-25.1% | $98.7M+200.8% | $114.8M+94.4% | $73.6Mn/m | $32.7M+116.2% | $32.8M-55.7% | $59.1M-70.6% |
| Retained Earnings | -$1.6Bn/m | -$1.5Bn/m | -$1.5Bn/m | -$1.5Bn/m | -$1.5Bn/m | -$1.5Bn/m | -$1.5Bn/m | -$1.4Bn/m |
TVTX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $109.1M+662.1% | $47.2M+846.5% | -$40.4Mn/m | $60.7Mn/m | $14.3Mn/m | $5.0Mn/m | -$42.2Mn/m | -$35.7Mn/m |
| Depreciation & Amortization | $5.2M-67.1% | $4.2M-69.8% | $25.2M+96.9% | $18.1M+50.0% | $15.8M+40.5% | $14.0M+35.5% | $12.8M+29.6% | $12.1M+27.4% |
| Stock-Based Compensation | $23.4M+108.1% | $21.8M+104.6% | $16.1M+40.5% | N/A | $11.3M+40.4% | $10.6M+7.3% | $11.5M+17.8% | N/A |
| Capital Expenditures | N/A | N/A | N/A | N/A | $140Kn/m | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | $14.2Mn/m | N/A | N/A | N/A |
| Investing Cash Flow | -$119.6M-238.2% | -$206.3M-4353.3% | $21.5M-47.8% | -$104.8Mn/m | $86.6M+87.7% | $4.8M-83.0% | $41.3M-60.6% | -$80.3Mn/m |
| Financing Cash Flow | $27.3Mn/m | $187.5M+12613.0% | $4.2M+13.1% | $26.7M-80.8% | -$65.3M-142141.3% | $1.5M+88.6% | $3.7Mn/m | $139.1M+112092.7% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TVTX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 98.7%-0.3pp | 98.7%0.0pp | 98.5%+4.2pp | 98.0%+1.4pp | 99.0%+1.6pp | 98.7%+2.5pp | 94.3%-2.1pp | 96.6% |
| Operating Margin | -30.3%-45.5pp | 2.3%+13.4pp | -29.0%+23.2pp | -25.0%+56.2pp | 15.1%+104.4pp | -11.1% | -52.2% | -81.2% |
| Net Margin | -23.3%-38.9pp | -20.5%-9.4pp | -29.2%+21.3pp | 2.1%+82.7pp | 15.6%+102.7pp | -11.1% | -50.4% | -80.6% |
| Return on Equity | -231.7%-266.7pp | -141.9%-103.0pp | -37.6%+88.0pp | 2.4%+104.4pp | 34.9% | -39.0%+425.9pp | -125.6%+58.1pp | -102.0%-57.1pp |
| Return on Assets | -6.2%-10.9pp | -4.3%-2.0pp | -6.7%+0.8pp | 0.4%+10.6pp | 4.8%+15.6pp | -2.3%+10.5pp | -7.5%+13.0pp | -10.1%+1.3pp |
| Current Ratio | 3.00+0.3x | 4.05+2.0x | 3.13+1.1x | 2.74+0.7x | 2.75+1.0x | 2.00-1.0x | 2.05-0.7x | 2.08-1.4x |
| Debt-to-Equity | N/A | N/A | N/A | 2.71-2.5x | 4.23 | 9.50-15.5x | 9.46+4.4x | 5.25+3.4x |
| Liabilities-to-Equity | 36.56+30.2x | 31.60+15.6x | 4.62-11.1x | 4.27-4.8x | 6.32 | 15.96-19.4x | 15.72+7.8x | 9.06+6.1x |
| Asset Turnover | 0.260.0x | 0.210.0x | 0.23+0.1x | 0.21+0.1x | 0.31+0.2x | 0.21+0.1x | 0.15+0.1x | 0.13+0.1x |
| FCF Margin | N/A | N/A | N/A | N/A | 8.6%+76.2pp | N/A | N/A | N/A |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Travere Therapeutics, Inc. TVTX | FY2025 | $490.7M | -$25.5M | -5.2% | $4.9B | 73/100 |
| Edgewise Therapeutics, Inc. EWTX | FY2025 | N/A | -$167.8M | N/A | $5.0B | — |
| Ionis Pharmaceuticals, Inc. IONS | FY2025 | $943.7M | -$381.4M | -40.4% | $4.8B | 70/100 |
| PTC Therapeutics, Inc. PTCT | FY2025 | $1.7B | $682.6M | 39.4% | $5.3B | 63/100 |
| Cogent Biosciences, Inc. COGT | FY2025 | N/A | -$328.9M | N/A | $5.0B | — |
| Scholar Rock Holding Corporation SRRK | FY2025 | $0 | -$377.9M | N/A | $5.3B | — |
Where Travere Therapeutics, Inc. Ranks
Frequently Asked Questions
Travere Therapeutics, Inc. (TVTX) reported $490.7M in total revenue for fiscal year 2025. This represents a 110.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Travere Therapeutics, Inc. (TVTX) revenue grew by 110.5% year-over-year, from $233.2M to $490.7M in fiscal year 2025.
No, Travere Therapeutics, Inc. (TVTX) reported a net loss of $121.5M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $25.5M, with a net profit margin of -5.2%.
Travere Therapeutics, Inc. (TVTX) had EBITDA of -$2.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
As of fiscal year 2025, Travere Therapeutics, Inc. (TVTX) had $93.0M in cash and equivalents against $311.7M in long-term debt.
Travere Therapeutics, Inc. (TVTX) had a gross margin of 97.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
Travere Therapeutics, Inc. (TVTX) had an operating margin of -12.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
Travere Therapeutics, Inc. (TVTX) had a net profit margin of -5.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Travere Therapeutics, Inc. (TVTX) has a return on equity of -22.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Travere Therapeutics, Inc. (TVTX) generated $37.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
Travere Therapeutics, Inc. (TVTX) had $605.2M in total assets as of fiscal year 2025, including both current and long-term assets.
Travere Therapeutics, Inc. (TVTX) invested $206.0M in research and development during fiscal year 2025.
Travere Therapeutics, Inc. (TVTX) had a current ratio of 2.74 as of fiscal year 2025, which is generally considered healthy.
Travere Therapeutics, Inc. (TVTX) had a debt-to-equity ratio of 2.71 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
Travere Therapeutics, Inc. (TVTX) had a liabilities-to-equity ratio of 4.27 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
Travere Therapeutics, Inc. (TVTX) had a return on assets of -4.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Travere Therapeutics, Inc. (TVTX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $4.9B as of Nov 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Travere Therapeutics, Inc. (TVTX) trades at 7.5x sales, its market capitalization divided by $651.0M revenue, trailing 12 months to September 30, 2026. The market capitalization is $4.9B as of Nov 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Travere Therapeutics, Inc. (TVTX) has an Altman Z-Score of 3.56, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
Travere Therapeutics, Inc. (TVTX) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Travere Therapeutics, Inc. (TVTX) reported a net loss of $25.5M while generating $37.8M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Travere Therapeutics, Inc. (TVTX) reported an operating loss of $62.8M against $10.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
Travere Therapeutics, Inc. (TVTX) scores 73 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.